Antares Pharma, Inc. (ATRS)

R&D to Revenue

7.88%

Fiscal year · Period ending:

ATRS logo

ATRS R&D to Revenue

Latest reported7.88%
ATRS FY R&D/Revenue (70.01% → 7.88%)
High-resolution chart · PNG

ATRS r&d to revenue history

Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.

Antares Pharma, Inc. R&D to Revenue — Annual fiscal periods
Period endingR&D to Revenue
7.8823%
6.7654%
8.5771%
19.3977%
24.1163%
40.456%
43.2159%
70.3277%
74.0276%
66.096%
40.7044%
68.6692%
95.0839%
138.9666%
68.2486%
88.5219%
153.2528%
129.1513%
92.2659%
91.4552%
101.6393%
61.3591%
69.4393%
127.8453%
69.244%
70.0147%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.